Laura Craver, PA
Physician Assistant · Oxnard, CANPI 1972047728
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (37.2%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Sanofi at 33.6% of the total. 2025 is the largest year on record at $9,985, more than ten times the $495 reported in 2022. Among physician assistant clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 159 payments — averaging $79.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$4K
- Jazz Pharmaceuticals Inc.$4K
- Inspire Medical Systems, Inc.$1K
- GSK$701
- AstraZeneca$688
- Harmony Biosciences LLC$502
- plus $1K from 17 others
What the payments were for
- Consulting fees$2,53220%
- Speaking & faculty fees$2,17817%
- Travel & lodging$2,79822%
- Food & beverage$4,67937%
- Education$4003%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 16 | $4,226 |
| Jazz Pharmaceuticals Inc. | 19 | $3,644 |
| Inspire Medical Systems, Inc. | 12 | $1,398 |
| GSK | 26 | $701 |
| AstraZeneca | 18 | $688 |
| Harmony Biosciences LLC | 11 | $502 |
| Regeneron Healthcare Solutions, Inc. | 10 | $287 |
| Boehringer Ingelheim | 10 | $248 |
| Lilly USA, LLC | 2 | $120 |
| Philips North America LLC | 5 | $119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $94 |
| Insmed, Inc. | 4 | $85 |
| Grifols USA, LLC | 4 | $83 |
| Axsome Therapeutics, Inc. | 4 | $81 |
| Baxter Healthcare | 2 | $62 |
| AbbVie | 3 | $55 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $54 |
| Electromed, Inc. | 2 | $34 |
| Mylan Specialty L.p. | 2 | $29 |
| Amgen | 1 | $27 |
| Viatris Specialty LLC | 1 | $17 |
| Phadia US Inc. | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,587 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 261 | $246,739 |
| OfevNintedanib Esylate | 15 | $181,528 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $35,776 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 37 | $27,342 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $25,742 |
| Spiriva RespimatTiotropium Bromide | 23 | $19,423 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $12,304 |
| XareltoRivaroxaban | 14 | $11,578 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 193 | $6,288 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 31 | $4,968 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $4,043 |
| BreynaBudesonide/Formoterol Fumarate | 35 | $3,853 |
| Eszopiclone | 16 | $2,400 |
| Roflumilast | 22 | $2,371 |
| Ventolin HfaAlbuterol Sulfate | 27 | $2,182 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $701 | $284,785320 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $248 | $228,29375 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $688 | $39,82060 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.
Other physician assistant in Oxnard
- Andrea NguyenIrvine$1M
- Mikhail AlperMadera$889K
- Erin JensenUpland$716K
- Franklin ClineSacramento$458K
- Carla CrespoMarina del Rey$297K
- Katherine OsakiEl Centro$274K
- Shawna JonesFountain Valley$266K
- Heather AustinSalinas$219K
- Andrea FoxStanford$172K
- Asma HussainiThousand Oaks$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.